Merck & Co Inc
XSGO : MRK$128.40+0.00%latest daily quote
Financials
CONDENSED CONSOLIDATED BALANCE SHEET
USD · reported units. Click a value to inspect its source.
| Reported line item | Jun 30, 2026 (current) | Dec 31, 2025 |
|---|---|---|
| Statement of Financial Position [Abstract] | ||
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | ||
| Short-term investments | ||
| Accounts receivable (net of allowance for doubtful accounts of $108 in 2026 and $97 in 2025) | ||
| Inventories (excludes inventories of $6,381 in 2026 and $5,681 in 2025 classified in Other assets - see Note 6) | ||
| Other current assets | ||
| Total current assets | ||
| Investments | ||
| Property, Plant and Equipment, at cost, net of accumulated depreciation of $22,729 in 2026 and $21,914 in 2025 | ||
| Goodwill | ||
| Other Intangibles, Net | ||
| Other Assets | ||
| Total Assets | ||
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | ||
| Trade accounts payable | ||
| Accrued and other current liabilities | ||
| Income taxes payable | ||
| Dividends payable | ||
| Total current liabilities | ||
| Long-Term Debt | ||
| Deferred Income Taxes | ||
| Other Noncurrent Liabilities | ||
| Merck & Co., Inc. Stockholders’ Equity | ||
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2026 and 2025 | ||
| Other paid-in capital | ||
| Retained earnings | ||
| Accumulated other comprehensive loss | ||
| Stockholders' equity before deduction for treasury stock | ||
| Less treasury stock, at cost: 1,108,460,187 shares in 2026 and 1,102,476,756 shares in 2025 | ||
| Total Merck & Co., Inc. stockholders’ equity | ||
| Noncontrolling Interests | ||
| Total equity | ||
| Liabilities and Equity |
31 line items · 2 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.